Mycapssa - (20 mg ; Delayed-release Capsules)

Generic Name	Octreotide Acetate	Innovator	Chiesi U.S.A
Dosage	20 mg ; Delayed-release Capsules	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	MYCAPSSA is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
****	*** \ *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events